A REVIEW ON BIOSIMILARS
*Zaberunnisa, Dr. M. Vijaya Bhargavi, Nagma Begum and Dr. M. Sumakanth
ABSTRACT
Over the last three decades, the tremendous claim for the financial success of biopharmaceutical products have seen the accessible switch for close copies of these biological product (biosimilars). Biologics is considered as one of the fastest growing sectors of the pharmaceutical industry, whereas a biosimilar is formally organized and approved replica of an originator biologic therapies. As the use of biological therapies expands, the number and diversity of induced autoimmune disorders should be expected to increase. The expiry of patent protection for many biological medicines has led to the development of biosimilars in UK or follow on biologics in USA. More specifically, the overarching aims of this article were to review the current issues revolving around biosimilar and take a critical glance related to definition; types of biosimilars, biosimilars differ from generic drugs, focusing/clinical standards on safety and efficacy, potential impact on financial burden in healthcare and future prospects of biosimilars in India, Europe and the rest of the world.
Keywords: Biopharmaceutical products, biologics, biological products, generic drugs, auto-immune disorders, safety and efficacy.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
